Earnings Release • Nov 8, 2017
Earnings Release
Open in ViewerOpens in native device viewer
Agfa Press Office Septestraat 27 B – 2640 Mortsel Belgium
Johan Jacobs Corporate Press Relations Manager
T +32 3 444 80 15 F +32 3 444 44 85 E [email protected]
"The progress made in the reorganization of our distribution channels for hardcopy film and the continued strong order book build-up in IT give us confidence in the short to medium term evolution of our HealthCare business.
Both our Inkjet business and our future-oriented specialty products performed well, while continued volume decreases, price erosion and aluminum price increases weighed on our prepress business.
The study on how to reorganize our HealthCare IT activities into a stand-alone legal entity structure within the Group is yielding encouraging results and October 10, the Board of Directors decided to initiate the first steps towards the execution of the plans. The management is fully committed to the success of this project, as we strongly believe that it is in the best interest of our Company, its stakeholders and its employees," said Christian Reinaudo, President and CEO of the Agfa-Gevaert Group.
| in million Euro | Q3 2016 | Q3 2017 | % change |
|---|---|---|---|
| Revenue | 625 | 593 | -5.1% |
| Gross profit (*) | 209 | 195 | -6.7% |
| % of revenue | 33.4% | 32.9% | |
| Recurring EBITDA (*) | 63 | 53 | -15.9% |
| % of revenue | 10.1% | 8.9% | |
| Recurring EBIT (*) | 49 | 40 | -18.4% |
| % of revenue | 7.8% | 6.7% | |
| Result from operating activities | 43 | 31 | -27.9% |
| Result for the period | 25 | 14 | -44.0% |
| Net cash from (used in) operating activities |
35 | 18 |
(*) before restructuring and non-recurring items
Most of the Agfa-Gevaert Group's growth engines performed well in the third quarter of 2017. The Group's top line decrease was mainly due to the strength of the Euro versus other currencies and the decline in the traditional businesses.
Excluding currency effects, the decrease would be limited to 2.9%, which shows a clear improvement compared to the first half of the year.
Impacted by adverse raw material effects, the Group's gross profit amounted to 195 million Euro, or 32.9% of revenue.
As a percentage of revenue, Selling and General Administration expenses amounted to 19.7%.
R&D expenses amounted to 35 million Euro, or 5.9% of revenue.
Recurring EBITDA (the sum of Graphics, HealthCare, Specialty Products and the unallocated portion) amounted to 8.9% of revenue, versus 10.1% in the third quarter of 2016. Recurring EBIT reached 6.7% of revenue, versus 7.8% in the previous year.
Restructuring and non-recurring items resulted in an expense of 9 million Euro, versus an expense of 6 million Euro in the third quarter of 2016.
The net finance costs decreased from 11 million Euro in the third quarter of 2016 to 8 million Euro.
Income tax expenses amounted to 9 million Euro, versus 7 million Euro in the previous year.
As a result of the elements mentioned above, the Agfa-Gevaert Group posted a net profit of 14 million Euro.
| in million Euro | Q3 2016 | Q3 2017 | % change |
|---|---|---|---|
| Revenue | 308 | 284 | -7.8% |
| Recurring EBITDA (*) | 23.9 | 14.2 | -40.6% |
| % of revenue | 7.8% | 5.0% | |
| Recurring EBIT (*) | 17.2 | 8.2 | -52.3% |
| % of revenue | 5.6% | 2.9% |
(*) before restructuring and non-recurring items
Adverse currency effects had a significant impact on Agfa Graphics' top line. Excluding these effects, revenue decreased by 4.7%. Continuing the good performance of the previous quarters, the business group's inkjet segment posted double-digit growth. Both the wide-format equipment product range and the inks for wide-format and industrial applications contributed to the revenue increase. Competitive pressure in the offset markets continued to weigh on prepress volumes and printing plate prices, although the price pressure started to ease somewhat due to increasing aluminum prices. In the prepress segment, the sustainable chemistry-free solutions continued to perform well. Agfa Graphics envisages to strengthen its market position with the recently introduced ECO³ program, which aims at giving customers access to a range of newly released value-added software solutions that will reduce costs, both in the prepress and press environment, while improving quality and productivity.
Mainly due to adverse raw material effects and competitive pressure effects, Agfa Graphics' gross profit margin decreased from 29.5% in the third quarter of 2016 to 27.8%. Recurring EBITDA amounted to 14.2 million Euro (5.0% of revenue),
versus 23.9 million Euro (7.8% of revenue) in last year's third quarter and recurring EBIT reached 8.2 million Euro (2.9% of revenue), versus 17.2 million Euro (5.6% of revenue).
Recently, Independent Printers Worldwide (IPW) recognized Agfa Graphics with their annual Vendor of the Year Award. Agfa Graphics partners with IPW members to drive out waste in production, improve productivity and make the shift from traditional printing to digital inkjet printing. IPW is a global procurement and selling group specializing in superior supplier programs and global print sales opportunities for independent printers.
In the field of inkjet, Agfa Graphics teamed up with Monotech Systems, India's leading products and solutions provider for the printing industry. Monotech Systems agreed to market Agfa Graphics' entire range of UV flatbed products in western and southern India.
In the field of prepress, Agfa Graphics completed the acquisition of software developer and reseller Bodoni Systems. Bodoni is based in Watford (UK). Also in prepress, important new equipment, software and consumables contracts were signed in – among other countries – the USA, Argentina, Australia, Brazil, Israel and Saudi Arabia.
| in million Euro | Q3 2016 | Q3 2017 | % change |
|---|---|---|---|
| Revenue | 271 | 258 | -4.8% |
| Recurring EBITDA (*) | 36.5 | 35.7 | -2.2% |
| % of revenue | 13.5% | 13.8% | |
| Recurring EBIT (*) | 29.8 | 29.5 | -1.0% |
| % of revenue | 11.0% | 11.4% |
Agfa HealthCare – third quarter 2017
(*) before restructuring and non-recurring items
On a currency comparable basis, Agfa HealthCare's revenue decline was limited to 3.2%. This decline was largely attributable to the hardcopy and classic X-ray product ranges. However, the top line impact of the reorganization of the hardcopy distribution channels in China started to abate in the third quarter. The situation should further normalize in the next quarters.
Most of the business group's growth engines performed well in the third quarter. The Direct Radiography (DR) product range posted strong double-digit growth figures. While the HealthCare Information Solutions range reported continuous top
line and order book growth, the Imaging IT Solutions range saw a temporary revenue slowdown. However, the continuously strong order book for the Enterprise Imaging platform ensures recurring medium and long term top line growth in this area.
Agfa HealthCare improved its gross profit margin from 39.9% in the third quarter of 2016 to 40.7%. As the success of the Enterprise Imaging platform incites Agfa HealthCare to speed up investments in its sales and service organization, recurring EBITDA decreased slightly from 36.5 million Euro (13.5% of revenue) in the third quarter of 2016 to 35.7 million Euro (13.8% of revenue). Recurring EBIT reached 29.5 million Euro (11.4% of revenue), versus 29.8 million Euro (11.0% of revenue) in last year's third quarter.
In the field of Imaging IT Solutions, Agfa HealthCare continued to win important contracts for its Enterprise Imaging platform. In Luxembourg, for instance, Agfa HealthCare and Fédération des Hôpitaux Luxembourgeois signed a contract for the installation of a national-level Enterprise Imaging platform. The solution will make all patient images accessible from any hospital in the country, while respecting patient rights and confidentiality. WellStar Health System – the largest not-for-profit health system in the state of Georgia (USA) – will use Agfa HealthCare's Enterprise Imaging platform to connect its clinicians with patient imaging information across multiple hospitals and hundreds of ambulatory care locations in the greater Atlanta metropolitan area. Recently, Agfa HealthCare and STC Solutions entered into a long-term collaboration to deliver cloud based advanced Enterprise Imaging services to healthcare providers in the Kingdom of Saudi Arabia. STC Solutions is the country's main IT services provider.
In the field of Integrated Care, Agfa HealthCare announced that it will integrate Mitch&Mates's solutions for administering and organizing patient questionnaires into its Integrated Care Suite. Agfa HealthCare's Integrated Care Suite is a webbased platform that supports personal care management and access to patient health information beyond hospital walls for patients as well as care providers.
In HealthCare Information Solutions, all five sites of the Gemeinschaftsklinikum Mittelrhein went live with Agfa HealthCare's ORBIS solution. In the German speaking countries of Europe, Agfa HealthCare is the leading provider of hospital information systems.
| in million Euro | Q3 2016 | Q3 2017 | % change |
|---|---|---|---|
| Revenue | 46 | 50 | 8.7% |
| Recurring EBITDA (*) | 3.4 | 4.9 | 44.1% |
| % of revenue | 7.4% | 9.8% | |
| Recurring EBIT (*) | 2.7 | 4.0 | 48.1% |
| % of revenue | 5.9% | 8.0% |
(*) before restructuring and non-recurring items
Agfa Specialty Products' revenue increased to 50 million Euro. The strong performances of the Printed Circuit Board business, Synaps Synthetic Paper and the Specialty Chemicals (including Orgacon Electronic Materials) more than compensated for the decline of the classic film products.
The business group's recurring EBITDA improved to 4.9 million Euro (9.8% of revenue). Recurring EBIT amounted to 4.0 million Euro (8.0% of revenue).
| in million Euro | 9m 2016 | 9m 2017 | % change |
|---|---|---|---|
| Revenue | 1,873 | 1,803 | -3.7% |
| Gross profit (*) | 634 | 600 | -5.4% |
| % of revenue | 33.8% | 33.3% | |
| Recurring EBITDA (*) | 189 | 152 | -19.6% |
| % of revenue | 10.1% | 8.4% | |
| Recurring EBIT (*) | 147 | 113 | -23.1% |
| % of revenue | 7.8% | 6.3% | |
| Result from operating activities | 147 | 99 | -32.7% |
| Result for the period | 75 | 49 | -34.7% |
| Net cash from (used in) operating activities |
82 | 14 |
(*) before restructuring and non-recurring items
| in million Euro | 9m 2016 | 9m 2017 | % change |
|---|---|---|---|
| Revenue | 936 | 893 | -4.6% |
| Recurring EBITDA (*) | 77.5 | 57.0 | -26.5% |
| % of revenue | 8.3% | 6.4% | |
| Recurring EBIT (*) | 57.5 | 38.7 | -32.7% |
| % of revenue | 6.1% | 4.3% |
(*) before restructuring and non-recurring items
| in million Euro | 9m 2016 | 9m 2017 | % change |
|---|---|---|---|
| Revenue | 802 | 761 | -5.1% |
| Recurring EBITDA (*) | 102.9 | 84.1 | -18.3% |
| % of revenue | 12.8% | 11.1% | |
| Recurring EBIT (*) | 83.2 | 65.3 | -21.5% |
| % of revenue | 10.4% | 8.6% |
(*) before restructuring and non-recurring items
| in million Euro | 9m 2016 | 9m 2017 | % change |
|---|---|---|---|
| Revenue | 135 | 148 | 9.6% |
| Recurring EBITDA (*) | 12.3 | 14.5 | 17.9% |
| % of revenue | 9.1% | 9.8% | |
| Recurring EBIT (*) | 9.7 | 12.0 | 23.7% |
| % of revenue | 7.2% | 8.1% |
(*) before restructuring and non-recurring items
This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of 14 November 2007 and in effect as of 2008. "The Board of Directors and the Executive Committee of Agfa-Gevaert NV, represented by Mr. Julien De Wilde, Chairman of the Board of Directors, Mr. Christian Reinaudo, President and CEO, and Mr. Kris Hoornaert, CFO, jointly certify that, to the best of their knowledge, the consolidated financial statements included in the report and based on the relevant accounting standards, fairly present in all material respects the financial condition and results of Agfa-Gevaert NV, including its consolidated subsidiaries. Based on our knowledge, the report includes all information that is required to be included in such document and does not omit to state all necessary material facts."
This statement is made in order to comply with new European transparency regulation enforced by the Belgian Royal Decree of 14 November 2007 and in effect as of 2008. "As with any company, Agfa is continually confronted with – but not exclusively - a number of market and competition risks or more specific risks related to the cost of raw materials, product liability, environmental matters, proprietary technology or litigation." Key risk management data is provided in the annual report available on www.agfa.com.
Contact:
Viviane Dictus Director Corporate Communication Septestraat 27 2640 Mortsel - Belgium T +32 (0) 3 444 71 24 E [email protected]
Corporate Press Relations Manager T +32 (0)3/444 80 15 E [email protected]
The full press release and financial information is also available on the company's website: www.agfa.com
Unaudited, consolidated figures following IFRS accounting policies.
| Q3 2016 | Q3 2017 | % change | 9m 2016 | 9m 2017 | % change | |
|---|---|---|---|---|---|---|
| Revenue | 625 | 593 | -5.1% | 1,873 | 1,803 | -3.7% |
| Cost of sales | (415) | (397) | -4.3% | (1,239) | (1,202) | -3.0% |
| Gross profit | 210 | 196 | -6.7% | 634 | 601 | -5.2% |
| Selling expenses | (84) | (81) | -3.6% | (257) | (255) | -0.8% |
| Research & Development expenses | (35) | (35) | - | (105) | (109) | 3.8% |
| Administrative expenses | (42) | (40) | -4.8% | (126) | (126) | - |
| Other operating income | 13 | 17 | 30.8% | 69 | 51 | -26.1% |
| Other operating expenses | (19) | (26) | 36.8% | (68) | (63) | -7.4% |
| Results from operating activities | 43 | 31 | -27.9% | 147 | 99 | -32.7% |
| Interest income (expense) - net Interest income |
(2) - |
(2) - |
- - |
(6) 1 |
(5) 1 |
-16.7% - |
| Interest expense | (2) | (2) | - | (7) | (6) | -14.3% |
| Other finance income (expense) - net | (9) | (6) | -33.3% | (34) | (23) | -32.4% |
| Other finance income | 2 | 4 | 100.0% | 10 | 9 | -10.0% |
| Other finance expense | (11) | (10) | -9.1% | (44) | (32) | -27.3% |
| Net finance costs | (11) | (8) | -27.3% | (40) | (28) | -30.0% |
| Profit (loss) before income taxes | 32 | 23 | -28.1% | 107 | 71 | -33.6% |
| Income tax expense | (7) | (9) | 28.6% | (32) | (22) | -31.3% |
| Profit (loss) for the period | 25 | 14 | -44.0% | 75 | 49 | -34.7% |
| Profit (loss) attributable to: | ||||||
| Owners of the Company | 22 | 12 | -45.5% | 68 | 44 | -35.3% |
| Non-controlling interests | 3 | 2 | -33.3% | 7 | 5 | -28.6% |
| Results from operating activities | 43 | 31 | -27.9% | 147 | 99 | -32.7% |
| Restructuring and non-recurring items | (6) | (9) | 33.3% | - | (14) | - |
| Recurring EBIT | 49 | 40 | -18.9% | 147 | 113 | -23.1% |
| Outstanding shares per end of period | 167,751,190 | 167,751,190 | 167,751,190 | 167,751,190 | ||
| Weighted number of shares used for calculation |
167,751,190 | 167,751,190 | 167,751,190 | 167,751,190 | ||
| Earnings per share (Euro) | 0.13 | 0.07 | 0.41 | 0.26 |
Unaudited, consolidated figures following IFRS accounting policies
| 2016 | 2017 | |
|---|---|---|
| Profit / (loss) for the period | 75 | 49 |
| Other Comprehensive Income, net of tax | ||
| Items that are or may be reclassified subsequently to profit or loss: | ||
| Exchange differences: | 15 | (35) |
| Exchange differences on translation of foreign operations | 4 | (35) |
| Exchange differences on disposal of foreign operations reclassified to profit or loss | 8 | - |
| Exchange differences on net investment hedge | 3 | - |
| Income tax on exchange differences on net investment hedge | - | - |
| Cash flow hedges: | 16 | 4 |
| Effective portion of changes in fair value of cash flow hedges | 8 | 21 |
| Changes in the fair value of cash flow hedges reclassified to profit or loss | - | (4) |
| Adjustments for amounts transferred to initial carrying amount of hedged items | 9 | (10) |
| Income taxes | (1) | (3) |
| Available-for-sale financial assets: | (1) | - |
| Changes in fair value of available-for-sale financial assets | (1) | - |
| Income taxes | - | - |
| Items that will not be reclassified subsequently to profit and loss: | - | - |
| Remeasurements of the net defined benefit liability | - | - |
| Income tax on remeasurements on the net defined benefit liability | - | - |
| Total other Comprehensive Income for the period, net of tax | 30 | (31) |
| Total Comprehensive Income for the period attributable to: | 105 | 18 |
| Owners of the Company | 101 | 15 |
| Non-controlling interests | 4 | 3 |
Unaudited, consolidated figures following IFRS accounting policies
| Q3 2016 | Q3 2017 | |
|---|---|---|
| Profit / (loss) for the period | 25 | 14 |
| Other Comprehensive Income, net of tax | ||
| Items that are or may be reclassified subsequently to profit or loss: | ||
| Exchange differences: | (3) | (10) |
| Exchange differences on translation of foreign operations | (4) | (10) |
| Exchange differences on disposal of foreign operations reclassified to profit or loss | 1 | - |
| Exchange differences on net investment hedge | - | - |
| Income tax on exchange differences on net investment hedge | - | - |
| Cash flow hedges: | 2 | (4) |
| Effective portion of changes in fair value of cash flow hedges | 2 | 1 |
| Changes in the fair value of cash flow hedges reclassified to profit or loss | - | (4) |
| Adjustments for amounts transferred to initial carrying amount of hedged items | 1 | (3) |
| Income taxes | (1) | 2 |
| Available-for-sale financial assets: | - | - |
| Changes in fair value of available-for-sale financial assets | - | - |
| Income taxes | - | - |
| Items that will not be reclassified subsequently to profit and loss: | - | - |
| Remeasurements of the net defined benefit liability | - | - |
| Income tax on remeasurements on the net defined benefit liability | - | - |
| Total other Comprehensive Income for the period, net of tax | (1) | (14) |
| Total Comprehensive Income for the period attributable to: | 24 | - |
| Owners of the Company | 22 | (1) |
| Non-controlling interests | 2 | 1 |
Unaudited, consolidated figures following IFRS accounting policies.
| 31/12/2016 | 30/09/2017 | |
|---|---|---|
| ASSETS Non-current assets |
1,066 | 1,030 |
| Intangible assets and goodwill | 621 | 598 |
| Property, plant and equipment | 198 | 189 |
| Investments in associates Financial assets |
6 10 |
6 9 |
| Trade receivables | 12 | 13 |
| Receivables under finance lease | 57 | 68 |
| Other assets | 13 | 10 |
| Deferred tax assets | 149 | 137 |
| Current assets | 1,286 | 1,251 |
| Inventories | 483 | 526 |
| Trade receivables | 493 | 478 |
| Current income tax assets | 64 | 62 |
| Other tax receivables | 25 | 23 |
| Receivables under finance lease | 30 | 14 |
| Other receivables | 13 | 17 |
| Other assets | 45 | 49 |
| Derivative financial instruments | 4 | 8 |
| Cash and cash equivalents | 129 | 74 |
| Total assets | 2,352 | 2,281 |
| EQUITY AND LIABILITIES | ||
| Equity | 252 | 260 |
| Equity attributable to owners of the Company | 215 | 230 |
| Share capital | 187 | 187 |
| Share premium | 210 | 210 |
| Retained earnings | 841 | 885 |
| Reserves | (79) | (75) |
| Translation reserve | 32 | (1) |
| Post-employment benefits: remeasurements of the net defined benefit liability | (976) | (976) |
| Non-controlling interests | 37 | 30 |
| Non-current liabilities | 1,382 | 1,308 |
| Liabilities for post-employment and long-term termination benefit plans | 1,269 | 1,224 |
| Other employee benefits | 8 | 7 |
| Loans and borrowings | 74 | 47 |
| Provisions | 4 | 5 |
| Trade payables | 6 | 6 |
| Deferred income | 2 | 2 |
| Deferred tax liabilities | 19 | 17 |
| Current liabilities | 718 | 713 |
| Loans and borrowings | 37 | 49 |
| Provisions | 74 | 69 |
| Trade payables | 219 | 222 |
| Deferred revenue and advance payments | 141 | 145 |
| Current income tax liabilities | 56 | 51 |
| Other tax liabilities | 37 | 28 |
| Other payables | 11 | 11 |
| Employee benefits | 132 | 132 |
| Other liabilities | 3 | 4 |
| Derivative financial instruments | 8 | 2 |
| Total Equity and Liabilities | 2,352 | 2,281 |
Unaudited, consolidated figures following IFRS accounting policies.
| 9m 2016 | 9m 2017 | Q3 2016 | Q3 2017 | |
|---|---|---|---|---|
| Profit (loss) for the period | 75 | 49 | 25 | 14 |
| Adjustments for: | ||||
| Depreciation, amortization and impairment losses | 42 | 39 | 14 | 13 |
| Changes in fair value of derivative financial instruments | 1 | (1) | (2) | 2 |
| Granted subventions | (6) | (7) | (2) | (3) |
| (Gains) / losses on sale of non-current assets | (10) | (1) | 0 | 0 |
| Net finance costs | 40 | 28 | 11 | 8 |
| Income tax expense | 32 | 22 | 7 | 9 |
| 174 | 129 | 53 | 43 | |
| Change in inventories | (26) | (62) | 4 | 3 |
| Change in trade receivables | 26 | (6) | 18 | (5) |
| Change in trade payables | (17) | 10 | (34) | (5) |
| Change in deferred revenue and advance payments | 17 | 11 | (5) | (16) |
| Change in other working capital | (37) | (12) | (4) | (3) |
| Change in non-current provisions | (34) | (40) | (12) | (15) |
| Change in current provisions | (4) | (2) | 20 | 23 |
| Cash generated from operating activities | 99 | 28 | 40 | 25 |
| Income taxes paid | (17) | (14) | (5) | (7) |
| Net cash from / (used in) operating activities | 82 | 14 | 35 | 18 |
| Interest received | 1 | 1 | 0 | 0 |
| Dividends received | 0 | 0 | 0 | 0 |
| Proceeds from sale of intangible assets | 2 | 1 | 1 | 0 |
| Proceeds from sale of property, plant and equipment | 1 | 2 | 0 | 0 |
| Proceeds from assets held for sale | 14 | 0 | 0 | 0 |
| Acquisition of intangible assets | (4) | (2) | 0 | 0 |
| Acquisition of property, plant and equipment | (25) | (27) | (8) | (11) |
| Changes in lease portfolio | 3 | 3 | 1 | 1 |
| Acquisition of subsidiary, net of cash acquired | 0 | (2) | 0 | 0 |
| Change in other investing activities | (4) | 1 | 0 | 0 |
| Net cash from / (used in) investing activities | (12) | (23) | (6) | (10) |
| Interest paid | (9) | (7) | (3) | (1) |
| Dividends paid to non-controlling interests | (12) | (10) | 0 | 0 |
| Proceeds from borrowings | 0 | 0 | 0 | 0 |
| Repayment of borrowings | (71) | (14) | (13) | (3) |
| Other financial flows | (20) | (10) | (5) | 2 |
| Net cash from / (used in) financing activities | (112) | (41) | (21) | (2) |
| Net increase (decrease) in cash and cash equivalents | (42) | (50) | 8 | 6 |
| Cash and cash equivalents at January 1 | 122 | 127 | ||
| Effect of exchange rate fluctuations | (1) | (3) | ||
| Cash and cash equivalents at end of the period | 79 | 74 |
Unaudited, consolidated figures following IFRS accounting policies.
| ATTRIBUTABLE TO OWNERS OF THE COMPANY | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| in million Euro | Share capital | Share premium | Retained earnings | Reserve for own shares |
Revaluation reserve |
Hedging reserve | Remeasurements of the net defined benefit liability |
Translation reserve |
Total | CONTROLLING S NON |
TOTAL EQUITY INTEREST |
| Balance at January 1, 2016 | 187 | 210 | 771 | (82) | 4 | (14) | (841) | (7) | 228 | 40 | 268 |
| Comprehensive income for the period Profit (loss) for the period Other comprehensive income, net of tax Total comprehensive income for the period |
- - - |
- - - |
68 - 68 |
- - - |
- (1) (1) |
- 16 16 |
- - - |
- 18 18 |
68 33 101 |
7 (3) 4 |
75 30 105 |
| Transactions with owners, recorded directly in equity Dividends |
- | - | - | - | - | - | - | - | - | (11) | (11) |
| Total transactions with owners, recorded directly in equity |
- | - | - | - | - | - | - | - | - | (11) | (11) |
| Balance at September 30, 2016 | 187 | 210 | 839 | (82) | 3 | 2 | (841) | 11 | 329 | 33 | 362 |
| Balance at January 1, 2017 | 187 | 210 | 841 | (82) | 2 | 1 | (976) | 32 | 215 | 37 | 252 |
| Comprehensive income for the period | |||||||||||
| Profit (loss) for the period | - | - | 44 | - | - | - | - | - | 44 | 5 | 49 |
| Other comprehensive income, net of tax | - | - | - | - | - | 4 | - | (33) | (29) | (2) | (31) |
| Total comprehensive income for the period | - | - | 44 | - | - | 4 | - | (33) | 15 | 3 | 18 |
| Transactions with owners, recorded directly in equity |
|||||||||||
| Dividends Total transactions with owners, recorded directly in equity |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
(10) (10) |
(10) (10) |
| Balance at September 30, 2017 | 187 | 210 | 885 | (82) | 2 | 5 | (976) | (1) | 230 | 30 | 260 |
--
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.